Response to "The 2021 von Willebrand disease guidelines: Clarity and controversy".

James, Paula D; Connell, Nathan T; Flood, Veronica H; Mustafa, Reem A

James, Paula D; Connell, Nathan T; Flood, Veronica H; Mustafa, Reem A.

Afiliação

James PD; Department of Medicine, Queen's University, Kingston, Ontario, Canada.
Connell NT; Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Flood VH; Division of Hematology/Oncology, Department of Pediatrics, Medical College of Wisconsin, Wauwatosa, Wisconsin, USA.
Mustafa RA; Outcomes and Implementations Unit, University of Kansas Medical Center, Kansas City, Kansas, USA.

Haemophilia ; 28(3): 371-372, 2022 05.

Article em En | MEDLINE | ID: mdl-35316557

Assuntos

Doenças de von Willebrand; Humanos; Fator de von Willebrand/uso terapêutico

Palavras-chave

clinical care; diagnosis; guidelines; management; recommendations; von Willebrand disease

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças de von Willebrand Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google